Genelux Corporation

US$1.96As of Sun 8 Nov 2026, 12:00 UTC
NASDAQ:GNLXHealthcare
Country USA
PE (Fwd) •••
TSR 4Y CAGR (24.76%)
Div yield —
ROE (177.93%)
Biotechnology
Beta (5Y) 0.66
PE TTM —
TSR TTM (75.74%)
Mkt cap US$87.83M
ROIC (103.15%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
$2.07
5.65%
(30.78%)
Hold 5|12|1|11|11
4Q25
1Q26
2Q26
3Q26
Earnings per share$
0.03
0.03
0.03
0.03
5.40%
(6.73%)
1.15%
6.52%
Revenue$M
7.110
7.534
7.507
7.575
3.54%
10.45%
3.92%
7.21%
Peers (US$87.83M)
Cap (US$)
PE
89.01M
131.4x
87.97M
—
Capital
TTM
5Y
10Y
Leveragex
0.783
(0.093)
(0.105)
EBIT/Intx
1.724
0.089
0.107
Own earn%
167.72
42.21
51.52
Sh yield%
31.98
34.94
31.70
Owners
Insiders/Inst%
14.05
23.47
Short interest%
1.70
SBC / revenue%
5.60
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
23
Op margin range%
28–37
$1 testx
—
Incr. ROIC%
3